Library — CHDR

Search

Filter

Older adults exercising ON TIME: protocol for a randomized controlled cross-over study to assess the effect of physical activity timing on insomnia severity.

Albalak G, Noordam R, van der Elst M, Kervezee L, Exadaktylos V, van Bodegom D, van Heemst D

Trials, 2024 Aug; 25(1):523

View publication
Fit for purpose of on-the-road driving and simulated driving: A randomised crossover study using the effect of sleep deprivation.

Koopmans I, Doll RJ, van der Wall H, de Kam M, Groeneveld GJ, Cohen A, Zuiker R

PloS one, 2023 Jun; 18(2):e0278300

View publication
The Benefit of Complete Response to Treatment in Patients With Chronic Spontaneous Urticaria-CURE Results.

Kolkhir P, Laires PA, Salameh P, Asero R, Bizjak M, Košnik M, Dissemond J, van Doorn M, Hawro T, Kasperska-Zajac A, Zajac M, Kocatürk E, Peter J, Parisi CAS, Ritchie CA, Kulthanan K, Tuchinda P, Fomina D, Kovalkova E, Khoshkhui M, Kouzegaran S, Papapostolou N, Du-Thanh A, Kamegashira A, Meshkova R, Vitchuk A, Bauer A, Grattan C, Staubach P, Bouillet L, Giménez-Arnau AM, Maurer M, Weller K

The journal of allergy and clinical immunology. In practice, 2023 Feb; 11(2):610-620.e5

View publication
The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder

Kasper Recourt, Peter de Boer, Rob Zuiker, Remy Luthringer, Justine Kent, Peter van der Ark, Ilse Van Hove, Joop van Gerven, Gabriel Jacobs, Luc van Nueten and Wayne Drevets

2019 Sep

View publication
Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration.

Muehlan C, Brooks S, Zuiker R, van Gerven J, Dingemanse J

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2019 Jul; 29(7):847-857

View publication
Central nervous system effects of the histamine-3 receptor antagonist CEP-26401, in comparison with modafinil and donepezil, after a single dose in a cross-over study in healthy volunteers.

Baakman AC, Zuiker R, van Gerven JMA, Gross N, Yang R, Fetell M, Gershon A, Gilgun-Sherki Y, Hellriegel E, Spiegelstein O

British journal of clinical pharmacology, 2019 Mar

View publication
A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity.

De Boer P, Drevets WC, Rofael H, van der Ark P, Kent JM, Kezic I, Parapatics S, Dorffner G, van Gerven J, Beneš H, Keicher C, Jahn H, Seiden DJ, Luthringer R

Journal of psychopharmacology (Oxford, England), 2018 Dec; 32(6):668-677

View publication
Accelerated development of the dual orexin receptor antagonist ACT-541468: Integration of a microtracer in the first-in-human study.

Muehlan C, Heuberger J, Juif PE, Croft M, van Gerven J, Dingemanse J

Clinical pharmacology and therapeutics, 2018 May

View publication
The effects of the nonselective benzodiazepine lorazepam and the α2 /α3 subunit-selective GABAA receptor modulators AZD7325 and AZD6280 on plasma prolactin levels.

Te Beek ET, Chen X, Jacobs GE, Nahon KJ, de Kam ML, Lappalainen J, Cross AJ, van Gerven JM, Hay JL

Clinical pharmacology in drug development, 2015 Feb; 4(2):149-54

View publication

«
1
2
3
»